Proteasome inhibitors induce caspase-dependent apoptosis and accumulation of p21(WAF1/Cip1) in human immature leukemic cells

European Journal of Haematology

Volumn 65, Issue 4, 2000, Pages 221-236

  Naujokat, Cord ^a,c   Sezer, Orhan ^a   Zinke, Hartmut ^a   Leclere, Anja ^b   Hauptmann, Steffen ^b   Possinger, Kurt ^a  

^a Med Klin Schwerpunkt Hamatologie   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Caspases; CD34+ cells; Leukemia; p21; p53; Proteasome; Proteasome inhibitors

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE; CASPASE INHIBITOR; CD34 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOSTATIC AGENT; DNA FRAGMENT; DOXORUBICIN; GEMCITABINE; LACTACYSTIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P53; ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CASP3 PROTEIN, HUMAN; CASPASE 3; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYSTEINE PROTEINASE INHIBITOR; DRUG DERIVATIVE; ENZYME INHIBITOR; LEUPEPTIN; MULTIENZYME COMPLEX; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE; ENZYME INHIBITION; FLOW CYTOMETRY; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ACUTE DISEASE; ADULT; CELL CULTURE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL STRAIN K 562; CELL STRAIN U937; CULTURE TECHNIQUE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IMMUNOLOGY; LEUKEMIA; METABOLISM; MITOSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACETYLCYSTEINE; ACUTE DISEASE; ADULT; ANTIGENS, CD34; APOPTOSIS; CASPASE 3; CASPASES; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTEINE PROTEINASE INHIBITORS; ENZYME INHIBITORS; FLOW CYTOMETRY; G2 PHASE; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; LEUKEMIA; LEUPEPTINS; MITOSIS; MULTIENZYME COMPLEXES; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; U937 CELLS;

EID: 0033623487     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.065004221.x     Document Type: Article

References (65)

1. Structure and functions of the 20S and 26S proteasomes
2. Roles of ubiquitin-mediated proteolysis in cell cycle control
3. Degradation of cell proteins and generation of MHC class I-presented peptides
4. The ubiquitin-proteasome pathway in cancer
5. Developmental changes of the 26S proteasome in abdominal intersegmental muscles of Manduca sexta during programmed cell death
6. Proteasomes play an essential role in thymocyte apoptosis
7. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons
8. Proteasomes are essential for yeast proliferation
9. p53-Dependent induction of apoptosis by proteasome inhibitors
10. Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells
11. Apoptosis induction resulting from proteasome inhibition
12. Activation of the cell death programm by inhibition of proteasome function
13. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
14. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
15. Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells
16. Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6
17. p27(Kip1) overexpression causes apoptotic death of mammalian cells
18. Overexpression of p21(WAF1/Cip1) induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines
19. Caspases: The executioners of apoptosis
20. Inhibition of CED-3/ICE-related proteases does not prevent celt death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak
21. Involvement of MACH, a novel MORT 1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death
22. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
23. Induction of apoptotic program in cell-free extracts: Requirment for dATP and cytochrome c
24. p53-Dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32β
25. Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by Bcl-2
26. Abnormally high expression of proteasomes in human leukemic cells
27. Regulation of gene expression of proteasomes (multi-protease complexes) during growth and differentiation of human hematopoietic cells
28. Proteasome inhibitors: Valuable new tools for cell biologists
29. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells
30. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells
31. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
32. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme
33. Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: A novel catalytic activity in proteasome
34. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine
35. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HsIV by a new class of inhibitors
36. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells
37. A giant protease with potential to substitute for some functions of the proteasome
38. A proteolytic system that compensates for loss of proteasome function
39. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: Comparison of bolus administration and continuous infusion
40. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study
41. Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis
42. Processing/activation of at least four interleukin-1β converting enzyme-like proteases occurs during the execution phase of apoptosis in human monocytic tumor cells
43. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl
44. Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in chinese hamster ovary cell cultures treated with cisplatin
45. Erythropietin (ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera
46. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53
47. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines
48. Frequent mutations in the p53 gene in human myeloid leukemia cell lines
49. Levels of p53 protein increase with maturation in human hematopoietic cells
50. The central executioners of apoptosis: Caspases or mitochondria?
51. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
52. In vivo ubiquitination and proteasome-mediated degradation of p53
53. Proteasome-dependent regulation of p21(WAF1/CIP1) expression
54. p53 Levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells
55. p53: Puzzle and paradigm
56. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
57. Molecular evolution of acute myeloid leukemia in relapse: Unstable N-ras and FLT3 genes compared with p53 gene
58. p53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
59. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lym-phocytic leukemic lymphocytes
60. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells
61. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformend lymphocytes after treatment with adriamycin by using a p53-independent pathway
62. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21(WAF1/CIP1) via C/EBPβ
63. Nuclear accumulation of p21Cipl at the onset of mitosis: A role at the G2/M-phase transition
64. Tumor growth inhibition induced in a murine model of Burkitt's lymphoma by a proteasome inhibitor
65. Proteasome inhibitors: A novel class of potent and effective antitumor agents